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Phosphodiesterase inhibitors (such as sildenafil) and 
endothelin receptor antagonist, bosentan, are effective for 
digital ulcer disease in systemic sclerosis (SSc-DU) and are 
endorsed in international treatment recommendations. 
Commissioning of high-cost drugs, such as bosentan, however, 
differs across devolved nations of the UK. We report a 
multicentre service evaluation project to examine ‘real world’ 
management of SSc-DU before and following the 2015 UK 
Scleroderma Study Group (UKSSG) guidance, across south-
west (SW) England and Wales. Results showed that iloprost 
and sildenafil use for SSc-DU was higher in patients in Wales 
prior to 2015. Between 2015–2017, sildenafil use for SSc-DU 
increased in SW England while remaining stable in Wales. 
Bosentan use for SSc-DU after 2015 in SW England increased, 
while remaining stable and proportionately lower in Wales. 
These findings demonstrate that differing commissioning 
guidance across devolved nations of the UK seems to 
contribute to geographic variation in patient care.
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remodelling. Digital vasculopathy is an important feature of SSc 
and manifests clinically as symptoms of Raynaud’s phenomenon 
(RP) and abnormal capillary morphology at the nailfold which are 
present in virtually all patients with SSc.1 Structural and functional 
digital vasculopathy can result in significant tissue ischaemia and 
tissue damage. Digital ulcers (DU) occur in approximately half of 
patients with SSc.2,3 SSc-DU are a major cause of disease-related 
morbidity in SSc.4,5 For some patients, DU occur as an isolated 
phenomenon but SSc-DU are recurrent in nature and relatively 
refractory to intervention in approximately 10% of patients.
The acute management for SSc-DU includes optimising analgesia 
and oral vasodilators (for example with calcium channel blockers, 
angiotensin II receptor antagonists, selective serotonin reuptake 
inhibitors and phosphodiesterase inhibitors) and/or intravenous 
vasodilator therapy (iloprost). Potential contributing factors, such as 
large vessel disease, should be treated aggressively and investigation 
and treatment of underlying infection is important. Magnetic 
resonance imaging can be useful to exclude deep infection and 
surgical debridement may be helpful in some circumstances.
The use of potent vasodilators, such as phosphodiesterase 
inhibitors (eg sildenafil), and the endothelin receptor antagonist 
bosentan are effective for secondary SSc-DU prevention 
and are endorsed in national and international treatment 
recommendations for the management of SSc.6–12
The existing commissioning of high-cost drugs, such as 
bosentan, differs across the devolved nations of the UK. The 
2015 NHS England Clinical Commissioning Policy on the use of 
sildenafil and bosentan for the management of SSc-DU closely 
aligns with contemporary UK-based guidelines produced by the 
UK Scleroderma Study Group (UKSSG) and by the British Society 
of Rheumatology (BSR).8–10 Prior to 2015, reimbursement for 
treatment with bosentan and sildenafil for SSc-DU in England 
required individual funding requests (IFRs), whereas in Wales, 
clinicians could prescribe sildenafil without prior authorisation. 
In 2009, the All Wales Medicines Strategy Group published an 
appraisal notice indicating that bosentan was not endorsed for 
use within NHS Wales for the treatment of DU in severe Raynaud’s 
disease, requiring clinicians to prepare an IFR.
Methods
We undertook a multicentre service evaluation project to examine 
‘real world’ management of SSc-DU before and following the  
Introduction
Systemic sclerosis (SSc) is a rare multisystem disease of unknown 
aetiology characterised by vasculopathy and aberrant tissue 
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significantly in SW England (23.9% vs 11.8%; p=0.049) while 
remaining stable in Wales. Bosentan use for SSc-DU in SW England 
increased by 47% after 2015 (5.9% to 8.7%; p=0.57), while 
remaining stable and proportionately lower in Wales over this 
period (8.7% vs 2.8%; p=0.44).
Discussion
The NHS England clinical commissioning policy enables specialist 
centres in England to prescribe sildenafil and/or bosentan for 
refractory SSc-DU disease in line with contemporary UKSSG and 
BSR guidance.9–11 The NHS England policy anticipated ∼1.7% 
of all SSc patients would satisfy the criteria for treatment with 
bosentan. Our regional data suggests ∼3% of all SSc patients 
have been managed with bosentan for SSc-DU. The high 
prevalence of recurrent SSc-DU (50% of those with a history of 
DU at 2015) and proportionately higher sildenafil use suggests 
sildenafil therapy may have prevented escalation to bosentan 
therapy in some patients in England. Sildenafil prescribing for 
SSc-DU in SW England rose to match that of Wales following the 
2015 NHS England commissioning guidance. In contrast, while 
bosentan prescribing for SSc-DU rose in England after 2015, it 
remained proportionately lower and remained stable in Wales 
(where IFRs were still required to prescribe bosentan).
Our service evaluation project benefits from being multicentre 
in nature. However, not all units in the region took part and it 
is therefore expected that not all patients in the region with 
SSc could be captured. Furthermore, other factors may have 
influenced prescribing practices across sites, such as prior clinical 
experience of bosentan and sildenafil prescribing influencing 
differing clinician preferences in their management of SSc-DU. 
Nevertheless, our findings suggest high-cost drug use for rare 
autoimmune rheumatic diseases such as SSc may be influenced 
by differing commissioning arrangements within the devolved 
nations of the UK. Consequently, this may result in geographic 
variation in clinical practice and inequitable patient access to 
effective treatments for important complications such as SSc-DU. 
Our findings may be replicated across other diseases in which 
divergent commissioning guidance within the separate devolved 
nations may also be leading to inequitable access to high-cost 
drugs.
2015 UKSSG guidance across south-west (SW) England and 
Wales. This collaborative service evaluation project was 
conducted by rheumatology trainees within the South West 
Audit Network (SWAN); comprising rheumatology centres across 
SW England and Wales. Clinical audit office and information 
governance approval was obtained at each site. Anonymised 
data on patient demographics, SSc-DU burden and SSc-DU 
management before and after 2015 was retrospectively 
collected from the case-notes of adult patients with an existing 
clinical diagnosis of SSc made prior to 2015 (according to the 
2013 American College of Rheumatology / European League 
Against Rheumatism classification criteria), using an MS Access 
form between September and December 2017. Patients with 
pulmonary arterial hypertension (PAH) were excluded from the 
analysis (and patients attending a dedicated regional SSc-PAH 
clinic in Bath were not included in the audit). The indication for 
the use of sildenafil or bosentan in each case was confirmed to 
be SSc-DU. The routine use of intravenous prostanoids for both 
RP and SSc-DU disease rendered establishing the main treatment 
indication (often both) challenging and data was consequently 
pooled. Results were analysed using IBM SPSS Statistics package 
version 24.
Results
The case-notes of 284 SSc patients were retrospectively assessed 
(68% SW England; 32% Wales); 11 of whom were excluded 
owing to the presence of SSc-PAH. The majority had limited 
cutaneous SSc (83.1%) with a mean disease duration of 10.4 years 
(standard deviation (SD) 8.2). One-hundred and thirteen patients 
(39.8%) had a history of DU prior to 2015 (85 in SW England). DU 
burden was available for 110 patients (a solitary DU in 23, 2–4 
previous DU in 55 and ≥5 previous DU in 32 patients). A higher 
burden of DU was associated with longer disease duration (9.0 
vs 13.5 years; p=0.04) and higher vasodilator medication usage 
(p=0.09). Intravenous iloprost (89.3% vs 48.2%; p=0.0001) and 
sildenafil (32.1% vs 11.8%; p=0.019) use for SSc-DU was higher 
in patients managed in Wales compared to England prior to 
2015 (Table 1). Sixty-one patients experienced new DU between 
2015–2017 (recurrence of DU in 46 patients and first DU in 15 
patients). Between 2015–2017, sildenafil use for SSc-DU increased 
Table 1. Use of intravenous prostanoids, sildenafil and bosentan for management of digital ulcer disease in 
systemic sclerosis in south-west England and Wales prior to and after 2015
Iloprost Sildenafil Bosentan Iloprost Sildenafil Bosentan Iloprost Sildenafil Bosentan
All regions, n=113 South-west England, n=85 Wales, n=28
SSc-DU 
management 
prior to 2015, 
n (%)
66 (58.4) 19 (16.8) 6 (5.3) 41(48.2) 
p=0.0001, 
vs Wales
10 (11.8) 
p=0.019, vs 
Wales
5 (5.9) 25 (89.3) 9 (32.1) 1 (3.6)
All regions, n=128 South-west England, n=92 Wales, n=36
SSc-DU 
management 
at 2017, n (%)
79 (61.7) 33 (25.8) 9 (7.0) 49 (53.3) 22(23.9) 
p=0.049, vs 
prior to 2015
8 (8.7) 30 (83.3) 11 (30.6) 1 (2.8)
Iloprost therapy was used for either Raynaud’s phenomenon or digital ulcer disease; p values were calculated using Fisher’s exact test. SSc-DU = digital ulcer 
disease in systemic sclerosis.
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Key points
> Intravenous iloprost and sildenafil use for SSc-DU was higher in 
patients managed in Wales compared to England prior to 2015.
> Between 2015–2017, sildenafil use for SSc-DU increased 
significantly in SW England while remaining stable in Wales.
> Bosentan use for SSc-DU after 2015 in SW England increased by 
47%, while remaining stable and proportionately lower in Wales 
over this period.
> Differing commissioning guidance across devolved nations of 
the UK seems to contribute to geographic variation in patient 
care. n
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